Inventor · disambiguated record
Romesh R. Subramanian
Also filed as: SUBRAMANIAN ROMESH · SUBRAMANIAN ROMESH R
70 granted patents·60 pending applications·1,343 citations·filing 2012–2025
99Inventor score
Files withDYNE THERAPEUTICS INC101TRANSLATE BIO MA INC12RANA THERAPEUTICS INC9MODERNATX INC4DYNE THERAPEUTICS LNC1
Top patents by PatentIndex Score
130 records- 0199US12370264B1Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2025·Granted Jul 29, 2025·2 cites·30 claims
- 0299US12357703B2Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skippingDYNE THERAPEUTICS INC·Filed 2025·Granted Jul 15, 2025·2 cites·30 claims
- 0399US12329824B1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2025·Granted Jun 17, 2025·4 cites·30 claims
- 0499US12329825B1Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subjectDYNE THERAPEUTICS INC·Filed 2025·Granted Jun 17, 2025·4 cites·30 claims
- 0599US12325753B2Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Jun 10, 2025·5 cites·30 claims
- 0699US12319743B2Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2024·Granted Jun 3, 2025·5 cites·30 claims
- 0799US12263225B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Apr 1, 2025·11 cites·30 claims
- 0899US12239717B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 0999US12239716B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Mar 4, 2025·13 cites·30 claims
- 1099US12173079B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2024·Granted Dec 24, 2024·14 cites·30 claims
- 1199US12173078B2Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2024·Granted Dec 24, 2024·14 cites·30 claims
- 1299US12144867B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 1399US12144868B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2024·Granted Nov 19, 2024·14 cites·19 claims
- 1499US12102687B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Oct 1, 2024·17 cites·30 claims
- 1599US12097263B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Sep 24, 2024·18 cites·21 claims
- 1699US12018087B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subjectDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 25, 2024·23 cites·27 claims
- 1799US12012460B2Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·22 cites·28 claims
- 1899US12005124B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Jun 11, 2024·23 cites·30 claims
- 1999US11986537B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted May 21, 2024·24 cites·19 claims
- 2099US11969475B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Apr 30, 2024·25 cites·30 claims
- 2199US11911484B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2021·Granted Feb 27, 2024·28 cites·22 claims
- 2299US11844843B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 19, 2023·30 cites·30 claims
- 2399US11839660B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 12, 2023·30 cites·16 claims
- 2499US11833217B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Dec 5, 2023·30 cites·20 claims
- 2599US11795233B2Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 24, 2023·32 cites·30 claims
- 2699US11795234B2Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotideDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 24, 2023·32 cites·30 claims
- 2799US11787869B2Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weaknessDYNE THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·32 cites·30 claims
- 2899US11771776B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Oct 3, 2023·32 cites·19 claims
- 2999US11759525B1Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Sep 19, 2023·32 cites·22 claims
- 3099US11679161B2Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 20, 2023·38 cites·25 claims
- 3199US11672872B2Anti-transferrin receptor antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·37 cites·21 claims
- 3299US11648318B2Anti-transferrin receptor (TFR) antibody and uses thereofDYNE THERAPEUTICS INC·Filed 2022·Granted May 16, 2023·37 cites·9 claims
- 3399US11638761B2Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted May 2, 2023·47 cites·24 claims
- 3499US11633498B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Apr 25, 2023·37 cites·30 claims
- 3599US11633496B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Apr 25, 2023·36 cites·20 claims
- 3699US11518816B2Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Dec 6, 2022·46 cites·23 claims
- 3799US11497815B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Nov 15, 2022·46 cites·20 claims
- 3899US11390682B2Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophyDYNE THERAPEUTICS INC·Filed 2022·Granted Jul 19, 2022·48 cites·23 claims
- 3999US11369689B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2022·Granted Jun 28, 2022·48 cites·20 claims
- 4099US11286305B2Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNADYNE THERAPEUTICS INC·Filed 2021·Granted Mar 29, 2022·64 cites·18 claims
- 4199US11248056B1Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2021·Granted Feb 15, 2022·50 cites·12 claims
- 4299US11168141B2Muscle targeting complexes and uses thereof for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2021·Granted Nov 9, 2021·53 cites·12 claims
- 4399US11111309B2Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4DYNE THERAPEUTICS INC·Filed 2021·Granted Sep 7, 2021·65 cites·21 claims
- 4498US12280122B2Muscle targeting complexes and uses thereof for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·5 cites·24 claims
- 4598US9790494B2Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkersTRANSLATE BIO MA INC·Filed 2015·Granted Oct 17, 2017·24 cites·20 claims
- 4697US11931421B2Muscle targeting complexes and formulations for treating myotonic dystrophyDYNE THERAPEUTICS INC·Filed 2023·Granted Mar 19, 2024·26 cites·7 claims
- 4795US12128109B2Muscle targeting complexes and formulations for treating dystrophinopathiesDYNE THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·17 cites·28 claims
- 4893US10059941B2Compositions and methods for modulating SMN gene family expressionTRANSLATE BIO MA INC·Filed 2013·Granted Aug 28, 2018·13 cites·38 claims
- 4993US9580708B2Multimeric oligonucleotides compoundsUHLMANN EUGEN·Filed 2012·Granted Feb 28, 2017·16 cites·25 claims
- 5092US10174323B2Compositions and methods for modulating ATP2A2 expressionTRANSLATE BIO MA INC·Filed 2013·Granted Jan 8, 2019·11 cites·31 claims
Showing the top 50 of 130 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →